American Century Companies Inc. Boosts Stock Position in Gilead Sciences, Inc. $GILD

American Century Companies Inc. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% in the third quarter, Holdings Channel reports. The institutional investor owned 3,805,549 shares of the biopharmaceutical company’s stock after acquiring an additional 416,410 shares during the quarter. American Century Companies Inc.’s holdings in Gilead Sciences were worth $422,416,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the third quarter worth about $26,000. Howard Hughes Medical Institute bought a new stake in Gilead Sciences in the 2nd quarter valued at about $30,000. Putney Financial Group LLC boosted its stake in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. MTM Investment Management LLC grew its position in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the last quarter. Finally, Kilter Group LLC bought a new position in Gilead Sciences in the 2nd quarter worth about $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $148.95 on Friday. The company has a market capitalization of $184.91 billion, a price-to-earnings ratio of 22.00, a P/E/G ratio of 1.88 and a beta of 0.36. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.98. The stock’s fifty day simple moving average is $136.10 and its 200-day simple moving average is $124.77.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 46.68%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 299,280 shares of company stock valued at $42,487,570 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead highlighted a twice-yearly HIV prevention injection with reported 99.9% efficacy (executive interview), reinforcing the company’s long-acting HIV/IP prevention market potential and upside to future sales if uptake and approvals follow. Johanna Mercier on Gilead’s HIV prevention innovation
• Positive Sentiment: New Phase 3 ARTISTRY-1 and ARTISTRY-2 data show the investigational single-tablet bictegravir/lenacapavir (BIC/LEN) maintained virological suppression when patients switched regimens — strengthens pipeline value and switch-market potential. Gilead’s Single-Tablet Regimen Maintained Virological Suppression
• Positive Sentiment: Daiwa raised its price target to $161 and kept an “outperform” rating, signaling buy-side confidence and giving shares technical/analyst momentum. Daiwa Securities Adjusts Price Target on Gilead Sciences
• Positive Sentiment: UBS reiterated a Buy with a $175 target, citing the advancing long-acting HIV franchise — another supportive analyst endorsement for upside. Gilead Sciences: Advancing Long-Acting HIV Franchise
• Positive Sentiment: Zacks issued a series of upward revisions to Gilead’s FY2026–FY2028 and multiple quarterly EPS forecasts (raises across 2026–2028), which supports higher medium-term earnings expectations. Zacks Research GILD Estimates
• Neutral Sentiment: Coverage pieces note Gilead has been outperforming the healthcare sector recently and analysts remain optimistic — supports momentum but is descriptive rather than new fundamental news. Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
• Neutral Sentiment: Industry/peer updates such as Kymera’s results were reported but are not directly material to Gilead’s near-term outlook. Kymera Therapeutics Q4 Highlights
• Negative Sentiment: Zacks trimmed its Q3 2026 EPS estimate slightly (from $2.34 to $2.30) — a small near-term downgrade within otherwise stronger multi-year raises; worth monitoring for quarterly variability. Zacks Lowers Q3 2026 Estimate
• Negative Sentiment: Merck reported promising Phase 3 results for a two-drug HIV regimen that matched Gilead’s Biktarvy, representing competitive pressure if approved. Investors should monitor regulatory outcomes and market-share implications. Merck’s New HIV Drug Shows Promise

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on GILD shares. Oppenheimer lifted their price target on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Royal Bank Of Canada boosted their price target on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Barclays began coverage on Gilead Sciences in a report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price target on the stock. Finally, Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.